Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Operetta 2: Ocrelizumab vs Fingolimod in Pediatric RRMS
NCT05123703Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- May 2022
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Roche. Started May 2022; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT05123703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05123703.